Abeona Therapeutics vs Crispr Therapeutics
Abeona Therapeutics is the larger business, with $5.8m of revenue in fiscal 2025 against $3.5m for Crispr Therapeutics (1.7 times as much). Abeona Therapeutics grew faster (66.3% against -90.6%). Abeona Therapeutics kept more of each dollar of sales as profit: a net margin of 1223.1% against -16569.8%. Crispr Therapeutics carries less debt relative to equity (0.0% against 12.6%).
| Latest fiscal year | Abeona TherapeuticsABEO, 2025 | Crispr TherapeuticsCRSP, 2025 |
|---|---|---|
| Revenue | $5.8m | $3.5m |
| Revenue growth | 66.3% | -90.6% |
| Net income | $71.2m | −$582m |
| Operating margin | -1536.9% | -18933.6% |
| Net margin | 1223.1% | -16569.8% |
| Return on equity | 81.8% | -30.2% |
| Free cash flow | −$84.3m | −$346m |
| Cash | $78.4m | $348m |
| Total debt | $20.0m | $0 |
| Debt to equity | 12.6% | 0.0% |
| Dividend per share | — | — |
| Dividend yield | — | — |
| Share buybacks | — | — |
| Employees | 226 | — |
| Market value | $242m | $4.83bn |
| Price vs our value range | — | — |
| Moat score | 9 (Weak) | 10 (Weak) |
| Insider trades, 12 months | 0 buys, 38 sales | 0 buys, 30 sales |